Form 8-K - Current report:
SEC Accession No. 0001104659-21-104289
Filing Date
2021-08-12
Accepted
2021-08-12 17:27:32
Documents
14
Period of Report
2021-08-06
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2125007d1_8k.htm   iXBRL 8-K 27260
2 EXHIBIT 10.1 tm2125007d1_ex10-1.htm EX-10.1 494859
6 GRAPHIC tm2125007d1_ex10-1sp6img001.jpg GRAPHIC 23245
  Complete submission text file 0001104659-21-104289.txt   832235

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA avte-20210806.xsd EX-101.SCH 3194
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE avte-20210806_lab.xml EX-101.LAB 34593
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE avte-20210806_pre.xml EX-101.PRE 22716
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2125007d1_8k_htm.xml XML 3727
Mailing Address 200 BERKELEY STREET FLOOR 18 BOSTON MA 02116
Business Address 200 BERKELEY STREET FLOOR 18 BOSTON MA 02116 617-443-2400
Aerovate Therapeutics, Inc. (Filer) CIK: 0001798749 (see all company filings)

EIN.: 831377888 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40544 | Film No.: 211168870
SIC: 2834 Pharmaceutical Preparations